Bladder (Urothelial, Transitional Cell) Cancer Clinical Trials

6 recruiting

Bladder (Urothelial, Transitional Cell) Cancer Trials at a Glance

7 actively recruiting trials for bladder (urothelial, transitional cell) cancer are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Manchester, Nanjing, and Rome. Lead sponsors running bladder (urothelial, transitional cell) cancer studies include Ekaterina Laukhtina, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Centre Hospitalier Universitaire de Saint Etienne.

Browse bladder (urothelial, transitional cell) cancer trials by phase

Treatments under study

About Bladder (Urothelial, Transitional Cell) Cancer Clinical Trials

Looking for clinical trials for Bladder (Urothelial, Transitional Cell) Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bladder (Urothelial, Transitional Cell) Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bladder (Urothelial, Transitional Cell) Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

Urothelial Carcinoma (UC)Bladder (Urothelial, Transitional Cell) CancerLiquid Biopsy
Tianjin Medical University Second Hospital300 enrolled1 locationNCT07441499
Recruiting
Not Applicable

Effectiveness of a Personalized 6-month Programme on Frailty in Older Patients Treated for Bladder or Kidney Cancer.

Bladder (Urothelial, Transitional Cell) CancerKidney (Renal Cell) Cancer
Centre Hospitalier Universitaire de Saint Etienne106 enrolled2 locationsNCT07073703
Recruiting
Phase 3

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

Bladder CarcinomaBladder NeoplasmMuscle Invasive Bladder Cancer (MIBC)+2 more
University of Rome Tor Vergata92 enrolled1 locationNCT07067749
Recruiting
Phase 2

Chemoablation for Low-Grade Bladder Cancer

Bladder (Urothelial, Transitional Cell) Cancer
Ekaterina Laukhtina47 enrolled1 locationNCT07019220
Recruiting

Selecting Hypoxic Tumours for Treatment Modification

Prostate CancerBladder (Urothelial, Transitional Cell) Cancer
University of Manchester30 enrolled1 locationNCT06787053
Recruiting
Phase 4

DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.

Bladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableUpper Tract Urothelial Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS135 enrolled1 locationNCT06820255
Recruiting
Phase 2

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Bladder (Urothelial, Transitional Cell) Cancer
The First Affiliated Hospital with Nanjing Medical University60 enrolled1 locationNCT06696742